Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

amifampridine phosphate

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Objective: To assess tolerability and efficacy of amifampridine phosphate versus placebo for symptomatic treatment of Lambert… Expand
Is this relevant?
Review
2019
Review
2019
PURPOSE OF REVIEW This article provides an update on the most recent advances in diagnostic procedures and therapeutic approaches… Expand
Is this relevant?
2018
2018
Objective: The aim of this study is to determine the safety and the efficacy of amifampridine phosphate in muscle-specific kinase… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2017
2017
PURPOSE The purpose of this study is to evaluate safety, tolerability, and pharmacokinetic (PK) properties of amifampridine… Expand
  • table I
  • table II
  • figure 2
  • figure 1
  • table III
Is this relevant?
2016
2016
OBJECTIVE We evaluated the efficacy and safety of amifampridine phosphate (Firdapse(®)) for symptomatic treatment in Lambert… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2015
2015
The clinical use of amifampridine phosphate for neuromuscular junction disorders is increasing. The metabolism of amifampridine… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2015
2015
PURPOSE Amifampridine (3,4-diaminopyridine) has been approved in the European Union for the treatment of Lambert-Eaton myasthenic… Expand
  • table I
  • table II
  • table III
Is this relevant?
Review
2014
Review
2014
There are already direct-to-consumer companies that have genetic counselors available, Goldman said. Even then, for many of these… Expand
Is this relevant?
2012
2012
Objective: To examine the pharmacogenomics of amifampridine phosphate in healthy volunteers. Background Amifampridine phosphate… Expand
Is this relevant?